166 related articles for article (PubMed ID: 12959185)
1. Optimizing primary chemotherapy in ovarian cancer.
Markman M
Hematol Oncol Clin North Am; 2003 Aug; 17(4):957-68, viii. PubMed ID: 12959185
[TBL] [Abstract][Full Text] [Related]
2. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
3. [Docetaxel and ovarian cancer].
Ray-Coquard I
Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
[TBL] [Abstract][Full Text] [Related]
4. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
8. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
Markman M
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
[TBL] [Abstract][Full Text] [Related]
9. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
[TBL] [Abstract][Full Text] [Related]
10. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
[TBL] [Abstract][Full Text] [Related]
12. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Hsu Y; Sood AK; Sorosky JI
Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
Fujiwara K; Markman M; Morgan M; Coleman RL
Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
17. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
Rowan K
J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
[No Abstract] [Full Text] [Related]
18. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
19. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Rigas JR
Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
